|Videos|June 29, 2020

How Hospitals Can Replicate a COVID-19 Recovery Unit

Bradley Sherman, MD, shares insight as to what goes into a respiratory ventilator recovery unit.

Earlier this month, Northwell Health debuted a pair of specialized, acute ventilator recovery units (AVRU) at its Glen Cove Hospital and Northern Westchester Hospital in efforts to aid New York City-based patients with coronavirus 2019 (COVID-19) who are weaning off ventilator use.

The concept of these new units was to provide relief to the overburdened hospital staffs facing the brunt of the pandemic’s spread—as well as assist patients who have received tracheotomies while on ventilators and now require rehabilitation for severe muscle loss and physical weakness.

Combined, the hospitals have 17 beds in these new units designated to such patients, as the region has progressed to a phase of less strained and more informed emergency medicine practice during COVID-19.

In an interview with Contagion®, Bradley Sherman, MD, Medical Director and Chair of the Department of Medicine at Glen Cove Hospital, discussed how beneficial these units have proven, and how applicable they are to other hospitals now under a greater distress due to new and worsening COVID-19 cases.

“It’s a pretty labor-intensive staff unit, to really focus on aggressive weaning and physical therapy,” Sherman explained. “I do think for those people around the country who may be getting more of the wave as New York is coming down a little bit, I think there’s a need for these units, because it’s a way of decanting the ICUs.”


Related to this article

Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.